Growth via M&A Aerpio recently merged with Aadibio and pursued private financing to accelerate its pipeline, signaling readiness for strategic partnerships and asset monetization opportunities. Potential avenues include licensing, co-development, or asset acquisition discussions with interested buyers or licensors.

Partnership History The company has engaged in partnerships with EyePoint Pharmaceuticals and Gossamer Bio for asset development and licensing, demonstrating a track record of external collaboration. This history supports outreach for new licenses, co-development deals, or strategic collaborations.

Active Pipeline Current programs focus on inflammatory diseases and ocular conditions, creating demand for clinical development services, GMP manufacturing support, regulatory consulting, and packaging and supply chain services as assets move toward later-stage trials.

Outsourcing Reliance A very small team implies heavy reliance on outsourced vendors for R&D, manufacturing, and regulatory tasks, presenting opportunities to offer end-to-end CRO/CDMO solutions, data management, pharmacovigilance, and vendor-management services.

Regional Growth Based in Ohio, Aerpio could benefit from regional CDMOs, logistics, and supplier networks; positioning as a preferred local vendor for contract manufacturing, packaging, cold-chain distribution, and accelerated regulatory support within the Midwest biotech ecosystem.